We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...

Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...

We feel now is a pretty good time to analyse Zai Lab Limited's ( NASDAQ:ZLAB ) business as it appears the company ...

Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Bank of America Securities analyst David Li maintained a Buy rating on Zai Lab (ZLAB – Research Report) on January 14 and set a price target of ...

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for ...

Zai Lab (ZLAB) announced topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically ...

In a report released on January 14, David Li from Bank of America Securities maintained a Buy rating on Zai Lab (ZLAB – Research Report), with ...